Revolutionary study: New combination therapy protects kidneys in diabetes!

Revolutionary study: New combination therapy protects kidneys in diabetes!

What does that mean for patient: inside with diabetes -related kidney damage? A new phase 2 study illustrates that the combination of a dual therapy with the SGLT2 inhibitor and the mineralocorticoid receptor antagonist Finerenon can significantly reduce albuminuria in patients with diabetic nephropathy. These results were recently presented at the annual congress of the European Renal Association (ERA) in Vienna and found their way into the renowned New England Journal of Medicine (Ärzteblatt).

In the study, it was examined how SGLT2 inhibitors can affect the disease progression in chronic kidney disease (CKD) together with Finerenon. The researchers: Inside, a retrospective analysis with 98 CKD patients led through and sorted them into different groups. The positive trend? The patients who received combination therapy showed impressive results: 96 % of the participants in this group were able to reduce their albuminuria of over 50 %. For comparison: In the monotherapy group of the SGLT2 inhibitors, this value was 50 % and 59 % (pmc).

significant results and the outlook on future therapies

Another plus point of combination therapy? The researchers: Inside, there were no increased risks of hyperkalaemia, which they emphasize as promising for the treatment of CKD patients. Nevertheless, the specific potassium values ​​between the groups vary; The finerenon group showed a significant increase in +0.4 mmol/l, while the monotherapy groups remained stable. These results testify to the possibility of developing a wide -ranging and safe therapy option (PMC).

By combining SGLT2 inhibitors and finerenon, the albuminuria could be reduced even more effectively, which is crucial for the quality of life of those affected at the end of the day. The author: However, warned of the study of the study, such as the small sample size, and emphasized the need for larger prospective studies to validate these results.

The context of heart failure

But progress is not only emerging in kidney therapy, research does not stand still in the area of ​​heart failure. AT1 receptor antagonists have proven to be promising in order to reduce cardiovascular morbidity in patients: inside that cannot take ACE inhibitors. Studies show that the combination of AT1 receptor blockers with ACE inhibitors and other established therapies such as beta blockers and spironolactone could bring additional advantages (Drug therapy.

Overall, the perspectives look promising in both kidney and heart therapy. The combination therapies not only seem to be better, but could also open new doors to future treatments.